TY - JOUR
T1 - Early life infection and proinflammatory, atherogenic metabolomic and lipidomic profiles in infancy
T2 - a population-based cohort study
AU - Mansell, Toby
AU - Saffery, Richard
AU - Burugupalli, Satvika
AU - Ponsonby, Anne Louise
AU - Tang, Mimi L.K.
AU - O'hely, Martin
AU - Bekkering, Siroon
AU - Smith, Adam Alexander T.
AU - Rowland, Rebecca
AU - Ranganathan, Sarath
AU - Sly, Peter D.
AU - Vuillermin, Peter
AU - Collier, Fiona
AU - Meikle, Peter
AU - Burgner, David
AU - the Barwon Infant Study Investigator Group
N1 - Funding Information:
Conclusions: Infants with a greater infection burden in the first year of life had proinflammatory and proatherogenic plasma metabolomic/lipidomic profiles at 12 months of age that in adults are indicative of heightened risk of cardiovascular disease, obesity, and type 2 diabetes. These findings suggest potentially modifiable pathways linking early life infection and inflammation with subsequent cardiometabolic risk. Funding: The establishment work and infrastructure for the BIS was provided by the Murdoch Children’s Research Institute (MCRI), Deakin University, and Barwon Health. Subsequent funding was secured from National Health and Medical Research Council of Australia (NHMRC), The Shepherd Foundation, The Jack Brockhoff Foundation, the Scobie & Claire McKinnon Trust, the Shane O’Brien Memorial Asthma Foundation, the Our Women’s Our Children’s Fund Raising Committee Barwon Health, the Rotary Club of Geelong, the Minderoo Foundation, the Ilhan Food Allergy Foundation, GMHBA, Vanguard Investments Australia Ltd, and the Percy Baxter Charitable Trust, Perpetual Trustees. In-kind support was provided by the Cotton On Foundation and CreativeForce. The study sponsors were not involved in the collection, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. Research at MCRI is supported by the Victorian Government’s Operational Infrastructure Support Program. This work was also supported by NHMRC Senior Research Fellowships to ALP (1008396); DB (1064629); and RS (1045161) , NHMRC Investigator Grants to ALP (1110200) and DB (1175744), NHMRC-A*STAR project grant (1149047). TM is supported by an MCRI ECR Fellowship. SB is supported by the Dutch Research Council (452173113).
Funding Information:
Toby Mansell: TM has received a postdoctoral fellowship from MCRI, is supported by NHMRC funding, has received travel support from MCRI and the University of Melbourne, and received a PhD scholarship from the University of Melbourne. Anne-Louise Ponsonby: ALP is an unpaid scientific advisor for, and has shares in, Dysrupt Labs. ALP has shares in Prevatex Pty Ltd. Mimi LK Tang: MLKT has received funding paid to Murdoch Childen's Research Institute (MCRI) from NHMRC, Prota Thera-putics, Abbott Nutrition, the Allergy and Immunology Foundation of Australasia, and the National Children's Research Centre of Ireland, and has received internal research funding from MCRI. MLKT is inventor of 2 patents owned by MCRI relating to allergy treatment and a method to induce tolerance to an allergen. MLKT is a member of the Advisory Boards for Pfizer (has received personal fee) and Anaphylaxis & Anaphylaxis Australia, and of allergy/anaphylaxis-related Committees for the World Allergy Organisation, the International Union of Immunological Societies, the Asia Pacific Association of Allergy Asthma and Clinical Immunology, the American Academy of Allergy Asthma and Immunology, and the Australasian Society of Clinical Immunology and Allergy. MLKT is employee of, and has share options in, Prota Therapeutics. MLKT is an Associate Editor for the Journal of Allergy and Clinical Immunology: Global. Martin O'Hely: MOH has stocks in Prevatex Pty Ltd. Siroon Bekkering: S Bekkering has received postdoctoral grants from the Dutch Heart Foundation and the Dutch Research Council, and travel support from the European Society for Atherosclerosis. Sarath Ranganathan: SR is Director of the Lung Foundation Australia. SR has stocks/options in Prevatex Pty Ltd. Peter Vuillermin: PV is an inventor on a patent relating to the relationship between maternal carriage of Prevotella. copri and offspring allergic disease, and has stocks/options in Prevatex Pty Ltd. David Burgner: DB has received an Investigator Grant and Project Grant from the Australian National Health and Medical Research Council (NHMRC). Barwon Infant Study Investigator Group: The other authors declare that no competing interests exist.
Publisher Copyright:
© Mansell et al.
PY - 2022/5/10
Y1 - 2022/5/10
N2 - Background: The risk of adult onset cardiovascular and metabolic (cardiometabolic) disease accrues from early life. Infection is ubiquitous in infancy and induces inflammation, a key cardiometabolic risk factor, but the relationship between infection, inflammation, and metabolic profiles in early childhood remains unexplored. We investigated relationships between infection and plasma metabolomic and lipidomic profiles at age 6 and 12 months, and mediation of these associations by inflammation. Methods: Matched infection, metabolomics, and lipidomics data were generated from 555 infants in a pre-birth longitudinal cohort. Infection data from birth to 12 months were parent-reported (total infections at age 1, 3, 6, 9, and 12 months), inflammation markers (high-sensitivity C-reactive protein [hsCRP]; glycoprotein acetyls [GlycA]) were quantified at 12 months. Metabolic profiles were 12-month plasma nuclear magnetic resonance metabolomics (228 metabolites) and liquid chroma-tography/mass spectrometry lipidomics (776 lipids). Associations were evaluated with multivariable linear regression models. In secondary analyses, corresponding inflammation and metabolic data from birth (serum) and 6-month (plasma) time points were used. Results: At 12 months, more frequent infant infections were associated with adverse metabolomic (elevated inflammation markers, triglycerides and phenylalanine, and lower high-density lipoprotein [HDL] cholesterol and apolipoprotein A1) and lipidomic profiles (elevated phosphatidylethanol-amines and lower trihexosylceramides, dehydrocholesteryl esters, and plasmalogens). Similar, more marked, profiles were observed with higher GlycA, but not hsCRP. GlycA mediated a substantial proportion of the relationship between infection and metabolome/lipidome, with hsCRP gener-ally mediating a lower proportion. Analogous relationships were observed between infection and 6-month inflammation, HDL cholesterol, and apolipoprotein A1. Conclusions: Infants with a greater infection burden in the first year of life had proinflammatory and proatherogenic plasma metabolomic/lipidomic profiles at 12 months of age that in adults are indicative of heightened risk of cardiovascular disease, obesity, and type 2 diabetes. These findings suggest potentially modifiable pathways linking early life infection and inflammation with subsequent cardiometabolic risk.
AB - Background: The risk of adult onset cardiovascular and metabolic (cardiometabolic) disease accrues from early life. Infection is ubiquitous in infancy and induces inflammation, a key cardiometabolic risk factor, but the relationship between infection, inflammation, and metabolic profiles in early childhood remains unexplored. We investigated relationships between infection and plasma metabolomic and lipidomic profiles at age 6 and 12 months, and mediation of these associations by inflammation. Methods: Matched infection, metabolomics, and lipidomics data were generated from 555 infants in a pre-birth longitudinal cohort. Infection data from birth to 12 months were parent-reported (total infections at age 1, 3, 6, 9, and 12 months), inflammation markers (high-sensitivity C-reactive protein [hsCRP]; glycoprotein acetyls [GlycA]) were quantified at 12 months. Metabolic profiles were 12-month plasma nuclear magnetic resonance metabolomics (228 metabolites) and liquid chroma-tography/mass spectrometry lipidomics (776 lipids). Associations were evaluated with multivariable linear regression models. In secondary analyses, corresponding inflammation and metabolic data from birth (serum) and 6-month (plasma) time points were used. Results: At 12 months, more frequent infant infections were associated with adverse metabolomic (elevated inflammation markers, triglycerides and phenylalanine, and lower high-density lipoprotein [HDL] cholesterol and apolipoprotein A1) and lipidomic profiles (elevated phosphatidylethanol-amines and lower trihexosylceramides, dehydrocholesteryl esters, and plasmalogens). Similar, more marked, profiles were observed with higher GlycA, but not hsCRP. GlycA mediated a substantial proportion of the relationship between infection and metabolome/lipidome, with hsCRP gener-ally mediating a lower proportion. Analogous relationships were observed between infection and 6-month inflammation, HDL cholesterol, and apolipoprotein A1. Conclusions: Infants with a greater infection burden in the first year of life had proinflammatory and proatherogenic plasma metabolomic/lipidomic profiles at 12 months of age that in adults are indicative of heightened risk of cardiovascular disease, obesity, and type 2 diabetes. These findings suggest potentially modifiable pathways linking early life infection and inflammation with subsequent cardiometabolic risk.
UR - http://www.scopus.com/inward/record.url?scp=85129543123&partnerID=8YFLogxK
U2 - 10.7554/eLife.75170
DO - 10.7554/eLife.75170
M3 - Article
C2 - 35535496
AN - SCOPUS:85129543123
SN - 2050-084X
VL - 11
JO - eLife
JF - eLife
M1 - e75170
ER -